196 related articles for article (PubMed ID: 33202891)
1. A Pilot Study Comparing the Efficacy of Lactate Dehydrogenase Levels Versus Circulating Cell-Free microRNAs in Monitoring Responses to Checkpoint Inhibitor Immunotherapy in Metastatic Melanoma Patients.
Bustos MA; Gross R; Rahimzadeh N; Cole H; Tran LT; Tran KD; Takeshima L; Stern SL; O'Day S; Hoon DSB
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33202891
[TBL] [Abstract][Full Text] [Related]
2. Integrated Assessment of Circulating Cell-Free MicroRNA Signatures in Plasma of Patients with Melanoma Brain Metastasis.
Bustos MA; Tran KD; Rahimzadeh N; Gross R; Lin SY; Shoji Y; Murakami T; Boley CL; Tran LT; Cole H; Kelly DF; O'Day S; Hoon DSB
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32630542
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Cell-Free microRNA by NGS Whole-Transcriptome Analysis in Cutaneous Melanoma Patients' Blood.
Tran KD; Gross R; Rahimzadeh N; Chenathukattil S; Hoon DSB; Bustos MA
Methods Mol Biol; 2021; 2265():475-486. PubMed ID: 33704735
[TBL] [Abstract][Full Text] [Related]
4. Cell-free plasma microRNAs that identify patients with glioblastoma.
Bustos MA; Rahimzadeh N; Ryu S; Gross R; Tran LT; Renteria-Lopez VM; Ramos RI; Eisenberg A; Hothi P; Kesari S; Barkhoudarian G; Takasumi Y; Cobbs C; Kelly DF; Hoon DSB
Lab Invest; 2022 Jul; 102(7):711-721. PubMed ID: 35013528
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic miRNA Signatures in Paired Tumor, Plasma, and Urine Specimens From Renal Cell Carcinoma Patients.
Bustos MA; Gottlieb J; Choe J; Suyeon R; Lin SY; Allen WM; Krasne DL; Wilson TG; Hoon DSB; Linehan JA
Clin Chem; 2024 Jan; 70(1):261-272. PubMed ID: 37791385
[TBL] [Abstract][Full Text] [Related]
6. Urine Cell-Free MicroRNAs in Localized Prostate Cancer Patients.
Koh Y; Bustos MA; Moon J; Gross R; Ramos RI; Ryu S; Choe J; Lin SY; Allen WM; Krasne DL; Wilson TG; Hoon DSB
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35625992
[TBL] [Abstract][Full Text] [Related]
7. Prospective Molecular Profiling of Circulating Tumor Cells from Patients with Melanoma Receiving Combinatorial Immunotherapy.
Lin SY; Chang SC; Lam S; Irene Ramos R; Tran K; Ohe S; Salomon MP; Bhagat AAS; Teck Lim C; Fischer TD; Foshag LJ; Boley CL; O'Day SJ; Hoon DSB
Clin Chem; 2020 Jan; 66(1):169-177. PubMed ID: 31672856
[TBL] [Abstract][Full Text] [Related]
8. Identification of a miRNA-based non-invasive predictive biomarker of response to target therapy in BRAF-mutant melanoma.
Ruggiero CF; Fattore L; Terrenato I; Sperati F; Salvati V; Madonna G; Capone M; Valenti F; Di Martino S; Mandoj C; Liguoro D; Castaldo V; Cafaro G; Simeone E; Vanella V; Russillo M; Conti L; Cuda G; Giannarelli D; Ascierto PA; Mancini R; Ciliberto G
Theranostics; 2022; 12(17):7420-7430. PubMed ID: 36438490
[No Abstract] [Full Text] [Related]
9. A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients.
Ono S; Oyama T; Lam S; Chong K; Foshag LJ; Hoon DS
Oncotarget; 2015 Mar; 6(9):7053-64. PubMed ID: 25749524
[TBL] [Abstract][Full Text] [Related]
10. Plasma MicroRNA Levels Following Resection of Metastatic Melanoma.
Latchana N; Abrams ZB; Howard JH; Regan K; Jacob N; Fadda P; Terando A; Markowitz J; Agnese D; Payne P; Carson WE
Bioinform Biol Insights; 2017; 11():1177932217694837. PubMed ID: 28469417
[TBL] [Abstract][Full Text] [Related]
11. The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis.
Stark MS; Klein K; Weide B; Haydu LE; Pflugfelder A; Tang YH; Palmer JM; Whiteman DC; Scolyer RA; Mann GJ; Thompson JF; Long GV; Barbour AP; Soyer HP; Garbe C; Herington A; Pollock PM; Hayward NK
EBioMedicine; 2015 Jul; 2(7):671-80. PubMed ID: 26288839
[TBL] [Abstract][Full Text] [Related]
12. Circulating MicroRNA Biomarkers in Melanoma: Tools and Challenges in Personalised Medicine.
Mumford SL; Towler BP; Pashler AL; Gilleard O; Martin Y; Newbury SF
Biomolecules; 2018 Apr; 8(2):. PubMed ID: 29701682
[TBL] [Abstract][Full Text] [Related]
13. No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study.
Guida M; Bartolomeo N; Quaglino P; Madonna G; Pigozzo J; Di Giacomo AM; Minisini AM; Tucci M; Spagnolo F; Occelli M; Ridolfi L; Queirolo P; De Risi I; Quaresmini D; Gambale E; Chiaron Sileni V; Ascierto PA; Stigliano L; Strippoli S; On Behalf Of The Italian Melanoma Intergroup Imi Study
Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33530579
[TBL] [Abstract][Full Text] [Related]
14. Plasma microRNA Profiles as a Potential Biomarker in Differentiating Adult-Onset Still's Disease From Sepsis.
Hu Q; Gong W; Gu J; Geng G; Li T; Tian R; Yang Z; Zhang H; Shao L; Liu T; Wan L; Jia J; Yang C; Shi Y; Shi H
Front Immunol; 2018; 9():3099. PubMed ID: 30687316
[TBL] [Abstract][Full Text] [Related]
15. Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p/TSC2/mTOR axis in metastatic pheochromocytoma/paraganglioma.
Calsina B; Castro-Vega LJ; Torres-Pérez R; Inglada-Pérez L; Currás-Freixes M; Roldán-Romero JM; Mancikova V; Letón R; Remacha L; Santos M; Burnichon N; Lussey-Lepoutre C; Rapizzi E; Graña O; Álvarez-Escolá C; de Cubas AA; Lanillos J; Cordero-Barreal A; Martínez-Montes ÁM; Bellucci A; Amar L; Fernandes-Rosa FL; Calatayud M; Aller J; Lamas C; Sastre-Marcos J; Canu L; Korpershoek E; Timmers HJ; Lenders JW; Beuschlein F; Fassnacht-Capeller M; Eisenhofer G; Mannelli M; Al-Shahrour F; Favier J; Rodríguez-Antona C; Cascón A; Montero-Conde C; Gimenez-Roqueplo AP; Robledo M
Theranostics; 2019; 9(17):4946-4958. PubMed ID: 31410193
[No Abstract] [Full Text] [Related]
16. Development and validation of plasma miRNA biomarker signature panel for the detection of early HIV-1 infection.
Biswas S; Haleyurgirisetty M; Lee S; Hewlett I; Devadas K
EBioMedicine; 2019 May; 43():307-316. PubMed ID: 31005516
[TBL] [Abstract][Full Text] [Related]
17. Identification of a plasma four-microRNA panel as potential noninvasive biomarker for osteosarcoma.
Lian F; Cui Y; Zhou C; Gao K; Wu L
PLoS One; 2015; 10(3):e0121499. PubMed ID: 25775010
[TBL] [Abstract][Full Text] [Related]
18. Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer.
Gonzales JC; Fink LM; Goodman OB; Symanowski JT; Vogelzang NJ; Ward DC
Clin Genitourin Cancer; 2011 Sep; 9(1):39-45. PubMed ID: 21723797
[TBL] [Abstract][Full Text] [Related]
19. A 9-microRNA Signature in Serum Serves as a Noninvasive Biomarker in Early Diagnosis of Alzheimer's Disease.
Guo R; Fan G; Zhang J; Wu C; Du Y; Ye H; Li Z; Wang L; Zhang Z; Zhang L; Zhao Y; Lu Z
J Alzheimers Dis; 2017; 60(4):1365-1377. PubMed ID: 29036818
[TBL] [Abstract][Full Text] [Related]
20. Identification of plasma microRNAs as new potential biomarkers with high diagnostic power in human cutaneous melanoma.
Fogli S; Polini B; Carpi S; Pardini B; Naccarati A; Dubbini N; Lanza M; Breschi MC; Romanini A; Nieri P
Tumour Biol; 2017 May; 39(5):1010428317701646. PubMed ID: 28466785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
